PAR14 COST MINIMIZATION ANALYSIS OF RITUXIMAB VERSUS INFLIXIMAB, ADALIMUMAB AND ETANERCEPT FOR RHEUMATOID ARTHRITIS FROM A PAYER PERSPECTIVE IN BRAZIL
Nov 1, 2007, 00:00
10.1016/S1098-3015(10)64929-7
https://www.valueinhealthjournal.com/article/S1098-3015(10)64929-7/fulltext
Title :
PAR14 COST MINIMIZATION ANALYSIS OF RITUXIMAB VERSUS INFLIXIMAB, ADALIMUMAB AND ETANERCEPT FOR RHEUMATOID ARTHRITIS FROM A PAYER PERSPECTIVE IN BRAZIL
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)64929-7&doi=10.1016/S1098-3015(10)64929-7
First page :
Section Title :
Open access? :
No
Section Order :
89